Novel Presentation of Pulmonary Atypical Carcinoid Tumor as Acute Pancreatitis

Anchit Bharat¹, Francesca Duncan², Mark Williams²

¹. Internal Medicine, Indiana University Health Ball Memorial Hospital, Muncie, USA ². Pulmonary and Critical Care Medicine, Indiana University School of Medicine, Indianapolis, USA

Corresponding author: Anchit Bharat, anchitbharat92@gmail.com

Abstract

Pulmonary neuroendocrine tumors (NETs) are a group of rare tumors that pose a high financial burden on patients and the United States healthcare system. The usual presenting symptoms include cough or wheezing, hemoptysis, or chest pain. Due to bronchial obstruction, patients may also present with recurrent pneumonia. Acute pancreatitis has yet to be documented as the initial manifestation of this disease. Atypical carcinoids - a subtype of NETs - are heterogeneous regarding their site of origin, biological behavior, and malignant potential. Studies show that the most common primary tumor site varies by race, with the lung being the most common in white patients and the rectum being the most common in Asian/Pacific Islander, American Indian/Alaskan Native, and African American patients. Certain carcinoid tumors, such as those of the rectum, are over-represented among the Black and Asian populations within the United States, suggesting the role of genetics in the development of this intriguing disease. Furthermore, the pancreas is not a usual site of metastasis for primary lung NET. Our case study describes the rare occurrence of a primary pulmonary NET (atypical carcinoid) metastasizing to the pancreas and presenting as acute pancreatitis.

Categories: Gastroenterology, Oncology, Pulmonology

Keywords: atypical carcinoid, acute pancreatitis, neuroendocrine tumors

Introduction

Pulmonary neuroendocrine tumors (NETs) are a group of rare pulmonary neoplasms characterized by neuroendocrine differentiation [1]. According to the World Health Organization (WHO), they are classified into four types: typical carcinoid, atypical carcinoid (AC), large cell neuroendocrine carcinoma, and small cell neuroendocrine carcinoma [2]. Based on the Surveillance, Epidemiology, and End Results program (2017), the incidence of lung NETs is 1.49 per 100,000 [3-4]. Depending on the pharmacological regimen, the total annual cost for a lung NET patient ranges from \$98,713 to \$124,383 [5]. This is in contrast to an average of \$39,891 for other lung cancers [6]. Not to mention the substantial indirect costs involved with this diagnosis. Hence, it becomes paramount for medical professionals to understand this disease process and be familiar with its rare presentations to provide high-value care. To date, there has been no reported association between lung AC and acute pancreatitis (AP). Our case study will describe this novel presentation and explore possible mechanisms of developing AP in a patient with lung AC.

Case Presentation

A 37-year-old Hakha Chin speaking female without any significant past medical history presented with epigastric pain, nausea, and vomiting for three weeks. She was admitted with acute pancreatitis in the setting of elevated lipase (1153 units/liter) and computed tomography abdomen and pelvis (CTAP) consistent with a large fluid collection arising from the neck of the pancreas (Figures 1A-1B).

Review began 09/22/2020

Review ended 10/13/2020

Published 10/20/2020

© Copyright 2020

Bharat et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

FIGURE 1: (A): Initial CTAP showing a large dominant fluid collection

How to cite this article

Bharat A, Duncan F, Williams M (October 20, 2020) Novel Presentation of Pulmonary Atypical Carcinoid Tumor as Acute Pancreatitis. Cureus 12(10): e11063. DOI 10.7759/cureus.11063

anterior to the pancreas, extending along the posterior aspect of the mid and distal stomach, arising from the neck of the pancreas, measuring 9.2 x 5.4 cm, with an estimated volume of 250 ml (marked with white pointers); (B): Peripancreatic edema with inflammatory stranding in the pancreatic tail (marked with white pointers)

CTAP: computed tomography of the abdomen and pelvis; cm: centimeter; ml: milliliter

Incidentally, CTAP also showed a left lower lung (LLL) mass-like consolidation (Figure 2), which was further evaluated with a CT chest. Imaging demonstrated the LLL mass (Figure 3A), a subcarinal lymph node (LN) (Figure 3B), and multiple suspicious nodular densities in the left breast.

FIGURE 2: Initial CTAP showing LLL mass-like consolidation measuring 4.1 x 3 cm

CTAP: computed tomography of the abdomen and pelvis; LLL: left lower lung; cm: centimeter

FIGURE 3: (A): CT chest coronal section showing a 4.0 X 4.1 X 3.0 cm LLL mass with (B): a subcarinal LN measuring 2.7 x 3.1 x 2.9 cm on the transverse section

CT: computed tomography; LLL: left lower lung; LN: lymph node; cm: centimeter

The patient was started on bowel rest, aggressive intravenous hydration, analgesics, and anti-emetics. Given a lack of risk factors (alcohol/illicit or over-the-counter drug use, hypertriglyceridemia, hypercalcemia, and family history for hepatic, biliary, or pancreatic disorders) following initial stabilization, a robust workup was undertaken to explore possible etiologies for patients' pancreatitis. Magnetic resonance cholangiopancreatography (MRCP) confirmed the above CTAP findings but was negative for biliary pathologies (Figures 4-5).

FIGURE 4: MRCP-confirmed pancreatitis with a rapidly enlarging loculated fluid collection in the lesser sac measuring 11.8 x 10.4 x 6.2 cm (red arrows). Pancreatic ductal dilation noted upstream of the mass

MRCP: magnetic resonance cholangiopancreatography; cm: centimeter

FIGURE 5: MRCP-confirmed pancreatitis with a rapidly enlarging loculated fluid collection in the lesser sac measuring 11.8 x 10.4 x 6.2 cm (red arrows). Pancreatic ductal dilation noted upstream of the mass

MRCP: magnetic resonance cholangiopancreatography; cm: centimeter

An endobronchial ultrasound-guided biopsy from mediastinal LN stations 7 and 11 revealed sheets and clusters of neuroendocrine cells with focal pseudo-acinar formation (Figure 6A-6B).

FIGURE 6: (A&B) Ultrasound-guided subcarinal LN biopsy from mediastinal LN stations 7 and 11 revealing sheets and clusters of neuroendocrine cells with focal pseudo-acinar formation (black arrows)

LN: lymph node

These cells demonstrated strong immunohistochemical staining for chromogranin, synaptophysin, with a Ki-67 labeling index of 5% and were negative for thyroid transcription factor-1, consistent with a metastatic atypical lung carcinoid tumor. Oncology was consulted for treatment recommendations and to establish outpatient care. Following the clinical improvement of pancreatitis, the patient was discharged with a strong outpatient follow-up. Outpatient breast biopsy revealed similar findings as the lymph node biopsy, with tumor cells showing neuroendocrine differentiation and strong immunohistochemical staining for synaptophysin and chromogranin with a Ki-67 < 20%. Positive emission tomography/computed tomography (PET/CT) (Figures 7-10) and magnetic resonance imaging (MRI) brain were obtained for staging (Figure 11).

FIGURE 7: PET/CT showing fluorodeoxyglucose (FDG) avid 4.5 x 4.2 x 3.6 cm LLL mass (red arrow) with max standardized uptake value (SUV) of 12 and FDG avid intramedullary metastasis in the lateral right 7th rib

PET/CT: positive emission tomography/computed tomography; FDG: fluorodeoxyglucose; LLL: left lower lung; SUV: standardized uptake value; cm: centimeter

FIGURE 8: PET/CT showing focal uptake of FDG by a 1.8 cm round and hypodense lesion (red arrow) in the body-tail of the pancreas (max SUV of 11)

PET/CT: positive emission tomography/computed tomography; FDG: fluorodeoxyglucose; cm: centimeter; SUV: standardized uptake value

FIGURE 9: PET/CT showing FDG avid 1.2 x 3.8 x 2.1 cm mediastinal LN station 7 (red arrow) metastatic atypical carcinoid (max SUV of 12.7) and a hypermetabolic left breast mass (blue arrow) with a maximum SUV of 13

PET/CT: positive emission tomography/computed tomography; FDG: fluorodeoxyglucose; cm: centimeter; LN: lymph node; SUV: standardized uptake value

FIGURE 10: PET/CT showing FDG avid 2.9 x 1.8 x 1.8 cm hilar LN at station 11L-12L (red arrow) metastatic atypical carcinoid (max SUV 12.6)

PET/CT: positive emission tomography/computed tomography; FDG: fluorodeoxyglucose; cm: centimeter; LN: lymph node; SUV: standardized uptake value

FIGURE 11: MRI brain sagittal view with numerous contrast-enhancing lesions (white arrows) within cerebral hemisphere measuring between

2-14 mm, the largest lesion being 12 x 13 x 14 mm within the superior left frontal lobe with mild surrounding vasogenic edema (red circle)

MRI: magnetic resonance imaging; mm: millimeter

These studies revealed widespread metastatic disease with approximately 20 cerebral and cerebellar lesions and possible metastasis to the pancreas. In light of Ki-67 being <20%, platinum-based chemotherapy was deemed questionable. The patient was considered a poor surgical candidate and was referred for whole-brain radiation, which she is currently pursuing for palliation.

Discussion

Due to its origin from proximal airways (as in our patient), lung AC commonly presents with lower respiratory symptoms: cough, wheezing, hemoptysis, chest pain, and recurrent pneumonia in the same pulmonary segment/lobe due to bronchial obstruction [7]. Our patient had no pulmonary symptoms throughout the clinical course even though she had a large LLL mass with significant mediastinal lymphadenopathy in multiple stations. No risk factors were identified for AP through extensive history, physical exam, laboratory workup, and multiple imaging. This presentation remains a medical mystery and the most novel aspect of our case, as AP has not been associated with lung AC before. After discussing with two radiologists, pathologists and gastroenterologists, we hypothesize that the AP was secondary to a metastatic spread of lung AC to the pancreas (Figure 7). This is supported by a focal uptake of FDG by the obstructing pancreatic lesion. The obstruction caused a proximal pancreatic ductal dilation with a failure to visualize the distal duct on MRCP (Figures 4-5), leading to a rapidly enlarging pancreatic cyst with necrotic material seen on imaging and the clinical presentation of pancreatitis. Furthermore, a relatively high SUV, resembling that of the lung AC supports the metastatic theory. So far, there is only one reported case study of such a spread [8]. Pancreatic biopsy remains the gold standard in proving our hypothesis but was deemed unnecessary, as it would contribute little to the management.

Atypical carcinoids are heterogeneous regarding the site of origin, biological behavior, and malignant potential. Genetic and epigenetic alterations may play a seminal role in these factors. Epigenetic studies have shown that the most common primary tumor site varied by race, with the lung being the most common in white patients, and the rectum being the most common in Asian/Pacific Islander, American Indian/Alaskan Native, and African American patients. Certain carcinoid tumors, such as those of the rectum, appear to be over-represented among the Black and Asian populations within the United States, suggesting the role of genetics in the development of this intriguing disease. More work needs to be done to identify potential biomarkers that could impact the diagnostics, prognostic stratification, and planning of personalized therapy [9].

Conclusions

With this article, we are bringing to light a novel presentation of atypical pulmonary carcinoid, which presented as acute pancreatitis. Racial differences are noted in the primary distribution of this tumor. Appropriate and speedy diagnosis is necessary to provide the patient's timely high-value care.

Additional Information

Disclosures

Human subjects: Consent was obtained by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. McMullan DM, Wood DE: Pulmonary carcinoid tumors. *Semin Thorac Cardiovasc Surg.* 2003, 15:289-300. [10.1016/s1043-0679\(03\)70009-4](https://doi.org/10.1016/s1043-0679(03)70009-4)
2. Fillinger J: Pathology of lung neuroendocrine tumors [Article in Hu]. *Magy Onkol.* 2018, 62:83-89.
3. Dasari A, Shen C, Halperin D, et al: Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. *JAMA Oncol.* 2017, 3:1335-1342. [10.1001/jamaoncol.2017.0589](https://doi.org/10.1001/jamaoncol.2017.0589)
4. Hauso O, Gustafsson BI, Kidd M, et al: Neuroendocrine tumor epidemiology: contrasting Norway and North America. *Cancer.* 2008, 113:2655-2664. [10.1002/cncr.23883](https://doi.org/10.1002/cncr.23883)
5. Broder MS, Cai B, Chang E, Yan T, Benson AB III: Treatment adherence, healthcare resource utilization, and costs in patients with lung neuroendocrine tumors (lung NETs) in the USA. *Curr Med Res Opin.* 2018, 34:2151-2156. [10.1080/03007995.2018.1505277](https://doi.org/10.1080/03007995.2018.1505277)

6. Warren JL, Yabroff KR, Meekins A, Topor M, Lamont EB, Brown ML: Evaluation of trends in the cost of initial cancer treatment. *J Natl Cancer Inst.* 2008, 100:888-897. [10.1093/jnci/djn175](https://doi.org/10.1093/jnci/djn175)
7. Gosain R, Mukherjee S, Yendamuri SS, Iyer R: Management of typical and atypical pulmonary carcinoids based on different established guidelines. *Cancers (Basel).* 2018, 10:12-14. [10.3390/cancers10120510](https://doi.org/10.3390/cancers10120510)
8. Soni A, Dogeas E, Juluri KR, Wolfgang CL, Hruban RH, Weiss MJ: The tail of neuroendocrine tumors from lung to pancreas: two rare case reports. *Int J Surg Case Rep.* 2014, 5:537-539. [10.1016/j.ijscr.2014.03.021](https://doi.org/10.1016/j.ijscr.2014.03.021)
9. Mafficini A, Scarpa A: Genetics and epigenetics of gastroenteropancreatic neuroendocrine neoplasms . *Endocr Rev.* 2019, 40:506-536. [10.1210/er.2018-00160](https://doi.org/10.1210/er.2018-00160)